B+
Bull case
30%
Probability
Target price
$44.00
+26.7% vs current
VCEL
VericelCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$37.00
+6.5% vs current
B-
Bear case
25%
Probability
Target price
$29.00
-16.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+53.8
Score
AI commentary
Primary-source tone is constructive because the May 7, 2026 earnings release showed a beat-and-raise profile with strong burn-care growth and steady margin guidance [#8-K-2026-05-07]. However, market reaction was softer than the release tone: VCEL traded at $33.47 on May 8, 2026 versus the May 7, 2026 anchor close of $35.13, a decline of about 4.7%. With low coverage and no clearly confirmed analyst revision wave yet, sentiment is best framed as cautious post-earnings monitoring rather than immediate thesis confirmation.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08catalystQ1 beat-and-raise needs price confirmationHigh impact
Vericel reported Q1 2026 revenue up 30% to $68.4M, burn care revenue up 91% to $12.0M, adjusted EBITDA up 195% to $9.6M, and raised full-year revenue guidance to $326M-$336M from $316M-$326M while reaffirming margin targets [#8-K-2026-05-07]. The key near-term question is whether stronger MACI and burn-care demand can outweigh the stock's negative day-after reaction.
2026-08-06eventUK MACI submission remains a dated regulatory milestoneHigh impact
Management said it remains on track to submit the MACI marketing authorization application to the U.K. MHRA in 2026 [#8-K-2026-05-07]. A visible regulatory filing would extend the growth narrative beyond the current U.S. knee franchise.
2027-04-01catalystBARDA-backed NexoBrid expansion can add funded burn-care optionalityHigh impact
Vericel disclosed a ten-year BARDA contract valued at up to $197M, including a $35M base period with about $10M over the next 12 months for initial procurement, vendor-managed inventory, and development work tied to potential blast-trauma use and manufacturing initiatives [#PR-2026-04-02]. This supports longer-duration burn-care growth, but funding timing and execution remain important qualifiers.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology